SCHEDULE: Adage Capital Reports 4.67% Stake in Traws Pharma
Beneficial Ownership Disclosure
Adage Capital Management, L.P. and its principals have reported a beneficial ownership of 4.67% of Traws Pharma, Inc.'s common stock as of September 30, 2025.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively referred to as the Reporting Persons, have filed an Amendment No. 1 to Schedule 13G.
- The filing discloses beneficial ownership of 330,000 shares of Traws Pharma, Inc. Common Stock.
- This represents 4.67% of the company's outstanding Common Stock.
- The percentage is calculated based on 7,063,829 shares of Common Stock outstanding as of August 12, 2025, as reported in Traws Pharma's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
- The Reporting Persons share both voting and dispositive power over these 330,000 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Traws Pharma, Inc.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative sentiment. It simply updates the public record on an institutional investor's stake.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by an institutional investor, Adage Capital Management, L.P., regarding its beneficial ownership in Traws Pharma, Inc. It reflects a standard reporting requirement for investors whose holdings fall below or are at certain thresholds, rather than an announcement related to broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Provides transparency regarding the holdings of a significant institutional investor, Adage Capital Management, L.P., and its principals, Robert Atchinson and Phillip Gross. This information can be used by other investors to gauge institutional interest and ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2025-08-12 | Date as of which 7,063,829 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-08-14 | Date Traws Pharma, Inc. filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. |
| 2025-09-30 | Date of event which requires the filing of this statement. |
| 2025-11-13 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Traws Pharma, Adage Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.